A common cause of hereditary thrombophilia is activated protein C resistance (APCR), and most cases result from factor V Leiden mutation. An APCR phenotype without association with factor V Leiden has been described. This transversal, observational, nonrandomized study evaluated these 2 phenomena in healthy indigenous and mestizo Mexican subjects (n = 4345), including 600 Mexican natives. No indigenous subjects had APCR, but 82 mestizo subjects did. After retesting, 50 subjects had a negative test. The remaining 32 subjects had factor V Leiden, giving a 0.85% prevalence of factor V Leiden in the mestizo Mexican population. Only 31% of APCR carriers had factor V Leiden. These results show a very low prevalence of APCR and factor V Leiden in Mexico. Except for factor V Leiden, there are no other mutations in the factor V gene responsible for the APCR phenotype. Acquired APCR is nearly twice as prevalent as the inherited variant.
Goldhaber SZEpidemiology of pulmonary embolism and deep vein thrombosis. In: Bloom AL, Forber CD, Thomas DP, Tuddenham ED, eds. Haemostasis and Thrombosis . New York, NY: Churchill Livingstone;1994:66-79.
2.
Dahlbäck B.Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood. 1995 ;85:607-614.
3.
Malm J., Laurell M., Nilsson IM, Dahlbäck B.Thromboembolic disease: critical evaluation of laboratory investigation. Thromb Haemost. 1992;68:7-13.
4.
Miletich JP, Prescott SM, White R., Majerus PW, Bovill EGInherited predisposition to thrombosis. Cell. 1993; 72:477-480.
5.
Tabernero MD , Tomas JF, Alberca I., Orfao A., López Borrasca A., Vicente V.Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis . Am J Hematol. 1991;36:249-254.
6.
Dahlbäck B.New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost.1995;74:139-148.
7.
Faioni EM, Franchi F., Asti D., Sacchi E., Bernardi F., Mannucci PMResistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost. 1993;70:1067-1071.
8.
Voorberg J., Roelse J., Koopman R., et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet1994;343:1535-1536.
9.
Koster T., Rosendaal FR, de Ronde H., Briet E., Vandenbroucke JP, Bertina RMVenous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet1993 ;342:1503-1506.
10.
Griffin JH, Evatt B., Wideman C., Fernandez JAAnticoagulant protein C pathway defective in a majority of thrombophilic patients . Blood. 1993;82:1989-1993.
11.
Halbmayer WM , Haushofer A., Schon R., Fischer M.The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis. 1994;5:51-57.
12.
Dahlbäck B.Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. J Intern Med. 1995;237:221-227.
13.
Clark P., Walker IDThe phenomenon known as acquired activated protein C resistance. Br J Haematol. 2001;115:767-773.
14.
Lisker R., Ramírez E., Babinsky V.Genetic structure of autochthonous populations of Meso-America: Mexico. Hum Biol. 1996, 68:395-404.
15.
Elice F., Fink L., Tricot G., Barlogie B., Zangari M.Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism . Br J Haematol. 2006;134:399-405.
16.
Bertina RM, Koeleman BP, Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
17.
Instituto Nacional de Estadística, Geografía e Informática. XII Censo Nacional de Población y Vivienda. 2000. Available at: www.inegi.gob.mx. Accessed July 19, 2007.
18.
Dahlbäck B. , Carlsson M., Svensson PJFamilial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
19.
Kisiel W., Canfield WM, Ericsson LH, Davie EWAnticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry. 1977; 16:5824-5831.
20.
Zivelin A., Griffin JH, Xu X., et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997;89:397-402.
Kane WH, Davie EWBlood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988;71:539-555.
23.
Rees DC, Cox M., Clegg JBWorld distribution of factor V Leiden. Lancet1995;346:1133-1134.
24.
Hallam PJ, Millar DS, Krawczak M., Kakkar VV, Cooper DNPopulation differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency. J Med Genet1995; 32:543-545.
25.
Cox MJ, Rees DC, Martinson JJ, Clegg JBEvidence for a single origin of factor V Leiden. Br J Haematol . 1996; 92:1022-1025.
26.
Castoldi E. , Lunghi B., Mingozzi F., Ioannou P., Marcheti G., Bernardi F.New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V Leiden mutation in Mediterranean populations and Indians. Thromb Haemost. 1997;78:1037-1041.
27.
Pepe G., Rickards O., Camacho Vanegas O., et al. Prevalence of factor V Leiden mutation in non-European populations . Thromb Haemost.1997;77:329-331.
28.
Hepner M., Roldan A., Pieroni G., et al. Frequency of factor V Arg506 to Gln mutation (FV Leiden) and activated protein C resistance in blood donors in Argentina. A preliminary study. Thromb Haemost.1997;78(suppl):226.
29.
Martinez E. , Tirado I., Vallve C., et al. Prevalence of resistance to activated protein C in patients with thrombosis in Spanish population. Thromb Haemost.1997;78(suppl): 223.
30.
Garcia-Gala JM , Alvarez V., Pinto CR, et al. Factor V Leiden (R506Q) and risk of venous thromboembolism: a case-control study based on the Spanish population . Clin Genet1997;52:206-210.
31.
van der Bom JG , Bots ML, Haverkate F., et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996;125:265-269.
32.
Kiechl S., Muigg A., Santer P., et al. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation . 1999;99:614-619.
33.
Sakata T., Kario K., Katayama Y., Matsuyama T., Kato H., Miyata T.Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res. 1996 ;82:235-244.
34.
De Visser MC , Rosendaal FR, Bertina RMA reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis . Blood. 1999;93:1271-1276.
35.
Rodeghiero F., Tosetto A.Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism . Ann Intern Med. 1999; 130:643-650.
36.
Tosetto A., Castaman G., Cappellari A., Rodeghiero F.The VITA Project: inheritability of resistance to activated protein C. Thromb Haemost. 2000;84:811-814.
37.
Gennari L., Blanco A.Alberto MF, Grosso S., Lazzari MAThe concomitant presence of lupus anticoagulant, anticardiolipin and anti-[beta]2-glycoprotein I antibodies could be associated with acquired activated protein C resistance in non-systemic lupus erythematosus patients. Br J Haematol.2003;121:527-529.
38.
Male C., Mitchell L., Julian J., et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood. 2001;97:844-849.
39.
Nojima J., Kuratsune H., Suehisa E., et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol . 2002;118:577-583.
40.
Benedetto C. , Marozio L., Tavella AM, Maulà V., Carmignani D., Curti A.Response to activated protein C decreases throughout pregnancy. Acta Obstet Gynecol Scand. 2002;81:1028-1032.
41.
Samama MM, Rached RA, Horellou MH, et al. Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone. Br J Haematol . 2003;123:327-334.
42.
Robertson L. , Wu O., Langhorne P., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2005; 132:171-196.
43.
Majluf-Cruz A., Silva-Estrada M., Sanchez-Barboza R., et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost. 2004;10:19-25.
44.
Makris TK, Krespi PG, Hatzizacharias AN, et al. Resistance to activated protein C and FV Leiden mutation in patients with a history of acute myocardial infarction or primary hypertension . Am J Hypertens. 2000;13:61-65.
45.
Olivieri O. , Friso S., Manzato F., et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol . 1995;91:465-470.
46.
van Vliet HA , Frolich M., Christella M., et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens . Hum Reprod. 2004;20:563-568.
47.
Gardiner C. , Mackie IJ, Furs SA, Piegsa K., Guillebaud J., Machin SJAcquired resistance to activated protein C is more pronounced in women receiving combined oral contraceptives containing desogestrel than levonorgestrel and is associated with low protein S levels . Br J Haematol.2003;121(suppl 1):62.
48.
Post MS, Rosing J., Van Der Mooren MJ, et al; Ageing Women and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU). Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women . Br J Haematol. 2002;119:1017-1023.
49.
Zangari M., Saghafifar F., Anaissie E., et al. Activated protein C resistance in the absence of FV Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis . 2002;13:187-192.
50.
De Lucia D. , de Vita F., Orditura M., et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori. 1997;83:948-952.
51.
Green D., Maliekel K., Sushko E., Akhtar R., Soff GAActivated protein C resistance in cancer patients. Haemostasis . 1997;27:112-118.
52.
Haim N., Lanir N., Hoffman R., Haim A., Tsalik M., Brenner B.Acquired protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001 ;110:91-96.
53.
De Stefano V., Leone G.Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica . 1995;80:344-356.
54.
Dahlbäck B.Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost. 1991;66:49-61.
55.
Guerrero F. , Arnaud C., Nguyen F., Boneu B., Sié P.Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation. Thromb Haemost. 2006;95:728-734.
